Drug name - Amitiza
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(a month from now) | |
| US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(a month from now) | |
| US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(2 months from now) | |
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(1 year, 11 months from now) | |
| US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(2 years from now) | |
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(4 years from now) | |
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(4 years from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(5 years from now) | |
Drugs and Companies using LUBIPROSTONE ingredient
Treatment: Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation; Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome; Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; method for the long term treatment of chronic constipation in a human subject
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 8MCG | CAPSULE;ORAL | Prescription |
| 24MCG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.